Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1649 1675
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18201516 | High Concentration Bispecific Antibody Formulations | Final Rejection | Janssen Biotech, Inc. |
| 17412346 | Stable Formulations Comprising A Bispecific EGFR/C-Met Antibody | Non-Final OA | Janssen Biotech, Inc. |
| 19433400 | LYOPHILIZED SOVATELTIDE-BASED INJECTABLE FORMULATION AND A PROCESS FOR PREPARATION | Non-Final OA | PHARMAZZ, INC. |
| 18258758 | AMYLOID-SPECIFIC ANTIBODIES AND USES THEREOF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17759792 | PH-SENSITIVE FC VARIANTS | Non-Final OA | Korea University Research and Business Foundation |
| 18248778 | COMBINATORIAL IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR PANCREATIC DUCTAL ADENOCARCINOMA TREATMENT | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17771353 | CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATIONS | Final Rejection | NOVARTIS AG |
| 17998634 | METHODS FOR DE-CLOAKING CANCER FROM THE IMMUNE SYSTEM THROUGH DOWNREGULATION OF CANCER-PRODUCED PREGNANCY SPECIFIC GLYCOPROTEIN | Non-Final OA | The Research Foundation for The State University of New York |
| 18015505 | MULTISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Non-Final OA | Legend Biotech USA Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy